Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About the Ochsner Journal
    • Editorial Board
  • More
    • Alerts
    • Feedback
  • Other Publications
    • Ochsner Journal Blog

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Ochsner Journal
  • Other Publications
    • Ochsner Journal Blog
  • My alerts
  • Log in
Ochsner Journal

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About the Ochsner Journal
    • Editorial Board
  • More
    • Alerts
    • Feedback
Case ReportCASE REPORTS AND CLINICAL OBSERVATIONS
Open Access

Bulbar Onset Amyotrophic Lateral Sclerosis in an African American Older Adult

Arielle Kasindi and Kathy Jo Carstarphen
Ochsner Journal December 2023, 23 (4) 353-356; DOI: https://doi.org/10.31486/toj.23.0045
Arielle Kasindi
1The University of Queensland Medical School, Ochsner Clinical School, New Orleans, LA
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathy Jo Carstarphen
1The University of Queensland Medical School, Ochsner Clinical School, New Orleans, LA
2Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA
MD, MPH, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kathyjo.carstarphen@ochsner.org
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Amyotrophic lateral sclerosis (ALS), a fatal neuromuscular disease, affects the motor tracts and anterior horn cells of the spinal cord, causing both upper and lower motor neuron dysfunction. ALS typically involves progressive peripheral weakness and mobility issues.

Case Report: An African American male in his early 70s presented to his primary care provider (PCP) with bulbar weakness and urinary tract symptoms. At presentation, and even later in the disease course, he ambulated well and did not report any limb issues. After some months of worsening symptoms of dyspnea, dysarthria, dysphagia, and urinary incontinence, a diagnosis of ALS was made via collaborative work between the PCP, a medical student, and various medical specialists including a neurosurgeon and neurologist. Because of the absence of limb abnormalities, the patient had difficulty accepting a diagnosis of ALS, thus delaying treatment onset.

Conclusion: Clinicians must consider the patient's presentation holistically so that they do not miss insidious, complex, or unique presentations. ALS can present with bulbar symptoms early in the disease course with no upper motor neuron/lower motor neuron involvement. Older adult African American males can present with ALS. Mistrust of health care systems and resistance to science based on religious beliefs can impact patient acceptance of diagnoses and engagement in treatments. Having a long-term relationship with a PCP who also represents the patient's community can influence patient willingness to accept diagnoses, especially those that are life-limiting.

Keywords:
  • Amyotrophic lateral sclerosis
  • delayed diagnosis
  • dysarthria
  • lower urinary tract symptoms
  • motor neuron disease
  • religion

INTRODUCTION

Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig disease, is a progressive neuromuscular disease with high morbidity and mortality.1 A study by Bianchi et al reported a 5-year survival rate of 24% and a median survival of 2.4 years after diagnosis.2 ALS is commonly diagnosed in patients between 50 and 68 years of age, with an average age of onset/diagnosis of 55 years.3 White males are more commonly affected than any other demographic.4 Patients typically present because of motor dysfunction in the periphery (limb weakness, gait instabilities, mobility issues), and signs are often progressive over time.5 ALS affects the anterior horn cells of the spinal cord, the area of the spinal cord in which motor neural tracts run from the primary motor cortex in the brain to the neuromuscular junctions in the peripheral muscles. In ALS, these tracts are affected, thus causing upper motor neuron and lower motor neuron dysfunctions. Having mixed signs of both is the classic presentation of ALS.5

We present the case of a patient with delayed diagnosis of progressive bulbar onset ALS.

CASE REPORT

An African American male in his early 70s initially presented to his primary care physician (PCP) with mild voice changes. His medical history was relevant for obstructive sleep apnea, benign prostatic hyperplasia, hypertension, and type 2 diabetes mellitus. The patient was the pastor of a large church, and his dysarthria progressively worsened during the next few months until his speech became largely unintelligible, resulting in his inability to lead the church choir in song or deliver a sermon. The patient also reported that he was experiencing dysphagia with solids. These symptoms became life-altering for the patient; he could not carry out his activities of daily living or efficiently perform his job.

The patient concurrently experienced dyspnea and urinary incontinence, initially thought to be attributable to his previously diagnosed obstructive sleep apnea and benign prostatic hyperplasia. Dyspnea was principally brought on with exertion, and the patient noted occasional wheezing. The patient's dyspnea became so concerning that he presented to the emergency department on multiple occasions.

Initially, the patient had significant issues with micturition and often experienced dribbling, straining, and nocturia that clinically correlated to his benign prostatic hyperplasia diagnosis. He took tamsulosin (Flomax) for these symptoms. However, his urinary urgency progressively worsened to urinary incontinence. He took a change of clothes wherever he went, anticipating incontinence. The urinary incontinence became increasingly distressing for the patient. His PCP later determined, after consulting a urology specialist, that these symptoms were not attributable to benign prostatic hyperplasia. Frequent and severe urinary incontinence is not commonly associated with benign prostatic hyperplasia but typically has a neurologic etiology.

The patient's dyspnea, dysarthria, dysphagia, and urinary incontinence were evaluated independently by several subspecialists. The patient received extensive workups, but results were negative for pathologic processes.

Stroke and cerebrovascular accident were initially the principal differential diagnoses. Because the patient's initial chief complaints were voice changes, dysphagia, and dysarthria, all signs of stroke,6 he was referred to vascular neurology. However, magnetic resonance imaging and computed tomography (CT) imaging were negative, ruling out a neurovascular cause of the symptoms.

The patient stated that he felt his eyelids drooping while watching television and endorsed worsening of speech symptoms if he spoke for long periods. Given the progressive worsening of muscles with repeated use,7 he was assessed for myasthenia gravis. However, serologic testing was negative.

In addition to the rapidly progressive voice changes, the patient frequently complained of dyspnea. Because of the patient's distant history of smoking, lung neoplasm was suspected. Additionally, paraneoplastic syndrome, such as Lambert-Eaton syndrome, could have explained the patient's neuromuscular issues.8 However, no lung mass was visualized on CT, the patient had no other signs or symptoms related to lung cancer, and all other pulmonary testing was normal. Lambert-Eaton syndrome would not fully explain all the issues the patient was experiencing.

Congestive heart failure typically presents with dyspnea, often orthopnea and paroxysmal nocturnal dyspnea.9 Although the patient reported normal breathing while he was lying flat, he experienced difficulties with obstructive sleep apnea. He had several risk factors for cardiovascular disease, so he was assessed for congestive heart failure and/or myocardial infarction. All cardiovascular examinations were negative.

In March 2021, after approximately 6 months of worsening symptoms, the patient's speech was so severely slurred and dysarthric that he was difficult to understand. He reported choking on his own saliva and experiencing severe dysphagia. A full neurologic examination showed reduced reflexes and bilateral upper extremity fasciculations. Otherwise, his neurologic examination was normal. The patient's PCP, a medical student, and a medical resident pieced together the components of the patient's presentation and specialist workups to arrive at the differential diagnosis of motor neuron disease. He was referred to a motor neurologist for further evaluation.

In April 2021, 7 months after the initial onset of symptoms of dysarthria, the patient was evaluated by a neurologist who specialized in neuromuscular conditions. A thorough examination in the neuromuscular clinic identified fasciculations in the left triceps muscle, left abductor hallucis muscle, and right abductor pollicis brevis muscle without noticed weakness. On ambulation, the patient's gait was slow and wide-based, and he was unable to walk on his toes. Table 1 presents the reflex and muscle strength findings from the examination. Slight drooling and right eye ptosis were also noted. The patient's speech was largely unintelligible with significant spastic dysarthria. The patient could not articulate his words, his voice was weak and nasal sounding, and his speech was slowed.

View this table:
  • View inline
  • View popup
Table 1.

Reflex and Muscle Strength Findings

ALS is largely a clinical diagnosis or a diagnosis of exclusion. Therefore, to confidently diagnose ALS, other disease states must first be ruled out. The clinical suspicion of ALS increased as the patient continued to lose motor function of various muscular groups. The detailed neuromuscular workup, with specific attention paid to subtle upper and lower motor neuron signs, supported the likelihood that the patient had ALS. Considering the negative findings from other investigations and the progressive nature of the patient's symptoms, ALS became the principal differential diagnosis.

No treatments for ALS are curative or can reverse the disease state. However, one pharmaceutical option—riluzole—has been shown to reduce disease progression.10 Riluzole works as an antagonist against glutamate release in the central nervous system and is one of the only US Food and Drug Administration–approved medications for the management of ALS. The patient was prescribed this therapy and enrolled at the Ochsner ALS Center, a multidisciplinary program that has the Certified Treatment Center of Excellence designation from the ALS Association.11

The patient initially rejected the ALS diagnosis. He had poor trust in the medical system and did not agree with the majority of what his medical providers told him regarding his diagnosis. He relied heavily on his religious background for guidance. As numerous providers pointed to the same diagnosis, he preferred to “pray for a miracle” and “rebuke the diagnosis.” The patient had a strong rapport with his PCP, who represented his community, and he trusted her medical decision-making. Regardless, he asked for a second opinion from a trusted neurosurgeon who had performed a surgery on his son that he described as “a miracle.” The patient felt that going to the Ochsner ALS Center would be an acceptance of the ALS diagnosis and he was extremely hesitant to do so. Consequently, several months elapsed before he presented to the ALS center after his diagnosis. However, once he began the program, the patient reported improvement of his symptoms. The ALS center focuses on multiple aspects of the disease, providing both physical therapy and respiratory therapy, and offers education, nutrition, therapy, support groups, familial assistance, and other interventions. Patients enrolled in the program receive help from speech therapy to assist with vocal and swallowing difficulties—the principal concerns of our patient. His vocal and bladder control and his ambulation improved. The patient learned ways to improve bladder control and received respiratory assistance. He agreed to take riluzole and was compliant with all recommended therapies.

However, 1 year after initial presentation, the patient declined rapidly and died while enrolled in hospice.

DISCUSSION

The patient's presentation and disease course were unique and caused difficulty diagnosing his condition. He did not present with the classic mixed upper motor neuron/lower motor neuron ALS signs and progressive mobility issues. Instead, his chief complaints at the initial presentation were dysarthria and dysphagia, indicating bulbar involvement.12 Additionally, the patient reported increasing dyspnea and urinary incontinence. Although bulbar onset ALS accounts for approximately 30% of ALS presentations/subtypes,13 respiratory muscle involvement is typically a late disease complication and not generally present at disease onset.14 Additionally, approximately 26.3% of ALS patients report urgency urinary incontinence.15 This constellation of symptoms, the lack of obvious limb involvement, and the patient's age and ethnicity represent a rare presentation for ALS.16

As outlined in Table 2, 7 months elapsed from presentation to diagnosis. If the patient had had mobility issues or obvious mixed upper motor neuron/lower motor neuron signs, perhaps his diagnosis would have been made sooner. Instead, his symptoms were evaluated separately rather than as signs of the same pathologic process. The patient was sent to several specialists with delays in assessing the symptoms globally and inferring a link between them. Each specialty team did an extensive workup, resulting in unnecessary use of medical resources (an issue of distributive justice), increased cost to the patient, and a heightened burden on an already overextended health system.

View this table:
  • View inline
  • View popup
Table 2.

Timeline of the Patient's Symptoms and Clinical Course

CONCLUSION

This case outlines the clinical significance of identifying a bulbar onset of ALS, particularly in patients of nondominant demographics. The importance of interdisciplinary communication is demonstrated in this case; the PCP coordinated care among the multiple teams and provided improved health outcomes. Additionally, this case highlights the importance of establishing strong patient rapport and considering sociologic and cultural influences on patients’ health literacy, capacity, and decision-making.

This article meets the Accreditation Council for Graduate Medical Education and the American Board of Medical Specialties Maintenance of Certification competencies for Patient Care and Medical Knowledge.

ACKNOWLEDGMENTS

When asked what he wanted to convey to readers, the patient's response was, “God will show you his miracle in healing me.” The authors thank Audrey Shawley for assis-tance with editing and formatting this manuscript. The authors have no financial or proprietary interest in the subject matter of this article.

  • ©2023 by the author(s); Creative Commons Attribution License (CC BY)

©2023 by the author(s); licensee Ochsner Journal, Ochsner Clinic Foundation, New Orleans, LA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (creativecommons.org/licenses/by/4.0/legalcode) that permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

REFERENCES

  1. 1.↵
    1. Al-Chalabi A,
    2. Hardiman O
    . The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9(11):617-628. doi: 10.1038/nrneurol.2013.203
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Bianchi E,
    2. Pupillo E,
    3. De Feudis A,
    4. Enia G,
    5. Vitelli E,
    6. Beghi E
    . Trends in survival of ALS from a population-based registry. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(5-6):344-352. doi: 10.1080/21678421.2021.2004167
    OpenUrlCrossRef
  3. 3.↵
    1. St Martin JL,
    2. Wang L,
    3. Kaprielian Z
    . Toxicity in ALS: TDP-43 modifiers and C9orf72. Neurosci Lett. 2020;716:134621. doi: 10.1016/j.neulet.2019.134621
    OpenUrlCrossRef
  4. 4.↵
    1. Longinetti E,
    2. Fang F
    . Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32(5):771-776. doi: 10.1097/WCO.0000000000000730
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Goutman SA
    . Diagnosis and clinical management of amyotrophic lateral sclerosis and other motor neuron disorders. Continuum (Minneap Minn). 2017;23(5, Peripheral Nerve and Motor Neuron Disorders):1332-1359. doi: 10.1212/CON.0000000000000535
    OpenUrlCrossRef
  6. 6.↵
    1. De Cock E,
    2. Batens K,
    3. Hemelsoet D,
    4. Boon P,
    5. Oostra K,
    6. De Herdt V
    . Dysphagia, dysarthria and aphasia following a first acute ischaemic stroke: incidence and associated factors. Eur J Neurol. 2020;27(10):2014-2021. doi: 10.1111/ene.14385
    OpenUrlCrossRef
  7. 7.↵
    1. Elrod RD,
    2. Weinberg DA
    . Ocular myasthenia gravis. Ophthalmol Clin North Am. 2004;17(3):275-309. doi: 10.1016/j.ohc.2004.05.014
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Kesner VG,
    2. Oh SJ,
    3. Dimachkie MM,
    4. Barohn RJ
    . Lambert-Eaton myasthenic syndrome. Neurol Clin. 2018;36(2):379-394. doi: 10.1016/j.ncl.2018.01.008
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Pang PS,
    2. Collins SP,
    3. Gheorghiade M,
    4. Butler J
    . Acute dyspnea and decompensated heart failure. Cardiol Clin. 2018;36(1):63-72. doi: 10.1016/j.ccl.2017.09.003
    OpenUrlCrossRef
  10. 10.↵
    1. Miller RG,
    2. Mitchell JD,
    3. Moore DH
    . Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;2012(3):CD001447. doi: 10.1002/14651858.CD001447.pub3
    OpenUrlCrossRef
  11. 11.↵
    Amyotrophic Lateral Sclerosis. Ochsner Health. Accessed January 30, 2022. ochsner.org/services/amyotrophic-lateral-sclerosis-als
  12. 12.↵
    1. Stegmann GM,
    2. Hahn S,
    3. Liss J,
    4. et al.
    Early detection and tracking of bulbar changes in ALS via frequent and remote speech analysis [published correction appears in NPJ Digit Med. 2020 Nov 20;3(1):154]. NPJ Digit Med. 2020;3:132. doi: 10.1038/s41746-020-00335-x
    OpenUrlCrossRef
  13. 13.↵
    1. Shellikeri S,
    2. Karthikeyan V,
    3. Martino R,
    4. et al.
    The neuropathological signature of bulbar-onset ALS: a systematic review. Neurosci Biobehav Rev. 2017;75:378-392. doi: 10.1016/j.neubiorev.2017.01.045
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Niedermeyer S,
    2. Murn M,
    3. Choi PJ
    . Respiratory failure in amyotrophic lateral sclerosis. Chest. 2019;155(2):401-408. doi: 10.1016/j.chest.2018.06.035
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Arlandis S,
    2. Vázquez-Costa JF,
    3. Martínez-Cuenca E,
    4. Sevilla T,
    5. Boronat F,
    6. Broseta E
    . Urodynamic findings in amyotrophic lateral sclerosis patients with lower urinary tract symptoms: results from a pilot study. Neurourol Urodyn. 2017;36(3):626-631. doi: 10.1002/nau.22976
    OpenUrlCrossRef
  16. 16.↵
    1. Masrori P,
    2. Van Damme P
    . Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020;27(10):1918-1929. doi: 10.1111/ene.14393
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Ochsner Journal: 23 (4)
Ochsner Journal
Vol. 23, Issue 4
Dec 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Ochsner Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Bulbar Onset Amyotrophic Lateral Sclerosis in an African American Older Adult
(Your Name) has sent you a message from Ochsner Journal
(Your Name) thought you would like to see the Ochsner Journal web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Bulbar Onset Amyotrophic Lateral Sclerosis in an African American Older Adult
Arielle Kasindi, Kathy Jo Carstarphen
Ochsner Journal Dec 2023, 23 (4) 353-356; DOI: 10.31486/toj.23.0045

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Bulbar Onset Amyotrophic Lateral Sclerosis in an African American Older Adult
Arielle Kasindi, Kathy Jo Carstarphen
Ochsner Journal Dec 2023, 23 (4) 353-356; DOI: 10.31486/toj.23.0045
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • CASE REPORT
    • DISCUSSION
    • CONCLUSION
    • ACKNOWLEDGMENTS
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Following Multiple Failed Reconstructions of a Distal Femur Fracture, Osseous Union Achieved After Superficial Femoral Artery Endarterectomy
  • Idiopathic Arginine Vasopressin Deficiency With Mild and Reversible Hypercalcemia
  • Management of Spontaneous Renal Arteriovenous Fistula in Pregnancy
Show more CASE REPORTS AND CLINICAL OBSERVATIONS

Similar Articles

Keywords

  • Amyotrophic lateral sclerosis
  • delayed diagnosis
  • dysarthria
  • lower urinary tract symptoms
  • motor neuron disease
  • religion

Ochsner Journal Blog

Current Post

Be Careful Where You Publish

Our Content

  • Home
  • Current Issue
  • Ahead of Print
  • Archive
  • Featured Contributors
  • Ochsner Journal Blog
  • Archive at PubMed Central

Information & Forms

  • Instructions for Authors
  • Instructions for Reviewers
  • Submission Checklist
  • FAQ
  • License for Publishing-Author Attestation
  • Patient Consent Form
  • Submit a Manuscript

Services & Contacts

  • Permissions
  • Sign up for our electronic table of contents
  • Feedback Form
  • Contact Us

About Us

  • Editorial Board
  • About the Ochsner Journal
  • Ochsner Health
  • University of Queensland-Ochsner Clinical School
  • Alliance of Independent Academic Medical Centers

© 2025 Ochsner Clinic Foundation

Powered by HighWire